Conception et réalisation d'une unité de synthèse automatisée pour la préparation du [18F]-FMPEP-d2.

[18F]-FMPEP-d2 制备的自动化合成单元的概念和实现。

• 批准号: 538082-2019
• 负责人: Guérin, Brigitte
• 金额: $ 1.82万
• 依托单位: Université de Sherbrooke
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=680385
• 关键词: Conception; et; alisation; une; unit

Inversago Pharma is a biotechnology company specializing in the development of new types of inverse agonists and antagonists of the cannabinoid type 1 (CB1) receptor for the treatment of several metabolic disorders such as diabetes (type II) in a more targeted way and therefore, causing fewer side effects. The company wants to perform efficacy and safety tests on this type of molecule by positron emission tomography (PET) imaging in order to market them, but to do this, Inversago Pharma must first find a way to synthesize a radiotracer for a better validation. For radioprotection reasons, complete automation of radiotracer synthesis is mandatory. A dedicated synthesis unit is also essential to avoid contamination and to reproduce optimal reaction and purification conditions. The research team of Pre Guérin therefore proposes, within the framework of this project, to design and build a synthesis unit or box in which all the stages of the radiotracer synthesis can be performed in an automated way while respecting both the radiation protection standards and the needs of the partner.

Inversago Pharma是一家生物技术公司，专门开发大麻素1型（CB1）受体的新型反向激动剂和拮抗剂，用于以更有针对性的方式治疗糖尿病（II型）等多种代谢疾病，因此副作用较少。该公司希望通过正电子发射断层扫描（PET）成像对这种类型的分子进行有效性和安全性测试，以便将其推向市场，但要做到这一点，Inversago Pharma必须首先找到一种合成放射性示踪剂的方法，以进行更好的验证。出于辐射防护的原因，放射性示踪剂合成的完全自动化是强制性的。专用的合成单元对于避免污染和重现最佳反应和纯化条件也是必不可少的。因此，Pre Guérin的研究团队建议，在该项目的框架内，设计和建造一个合成单元或盒，其中放射性示踪剂合成的所有阶段都可以以自动化的方式进行，同时尊重辐射防护标准和合作伙伴的需求。